Search research articles
Contact Us
Filters
Showing results (141-150 of 190) with videos related to
Page
of 19
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
December 14, 2011
A long duration of the prediagnostic symptomatic interval is not associated with an unfavourable prognosis in childhood medulloblastoma
Nicolas U Gerber, Katja von Hoff, André O von Bueren, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 3, 2009
Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT'91
Katja von Hoff, Bernward Hinkes, Nicolas U Gerber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 4, 2009
Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci
Stefan Pfister, Marc Remke, Axel Benner, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 12, 2022
Refining M1 stage in medulloblastoma: criteria for cerebrospinal fluid cytology and implications for improved risk stratification from the HIT-2000 trial
Christian Hagel, Veronika Sloman, Martin Mynarek, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 20, 2020
Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network
Loredana Amoroso, Victoria Castel, Gianni Bisogno, et al.
Child'S Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery
|
May 17, 2013
Somatostatin receptor subtype 2 (sst₂) is a potential prognostic marker and a therapeutic target in medulloblastoma
Marc Remke, Esther Hering, Nicolas U Gerber, et al.
Neuro-Oncology
|
April 5, 2024
Treatment response as surrogate to predict risk for disease progression in pediatric medulloblastoma with persistent magnetic resonance imaging lesions after first-line treatment
Denise Obrecht-Sturm, Lena Schömig, Martin Mynarek, et al.
Journal of Neurosurgery. Pediatrics
|
June 19, 2026
Incomplete tumor resection, central neuroradiological review, and second surgery in pediatric patients with intracranial ependymoma treated in the E-HIT2000 trial
Kara L Krajewski, Gertrud Kammler, Denise Obrecht-Sturm, et al.
Neuro-Oncology
|
April 28, 2021
Treatment of embryonal tumors with multilayered rosettes with carboplatin/etoposide induction and high-dose chemotherapy within the prospective P-HIT trial
B-Ole Juhnke, Marco Gessi, Nicolas U Gerber, et al.
Neuro-Oncology
|
June 3, 2026
Final report of the SIOP-CNS-GCT II protocol for germinoma-omitting radiotherapy boost is safe in localized disease in complete remission after chemotherapy
Gabriele Calaminus, Claire Alapetite, Rolf D Kortmann, et al.
Page
of 19
Search research articles
Search
Showing results (141-150 of 190) with videos related to
Sort By:
Page
of 19
European Journal of Cancer (Oxford, England : 1990)
|
December 14, 2011
A long duration of the prediagnostic symptomatic interval is not associated with an unfavourable prognosis in childhood medulloblastoma
Nicolas U Gerber, Katja von Hoff, André O von Bueren, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 3, 2009
Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HIT'91
Katja von Hoff, Bernward Hinkes, Nicolas U Gerber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 4, 2009
Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci
Stefan Pfister, Marc Remke, Axel Benner, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 12, 2022
Refining M1 stage in medulloblastoma: criteria for cerebrospinal fluid cytology and implications for improved risk stratification from the HIT-2000 trial
Christian Hagel, Veronika Sloman, Martin Mynarek, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 20, 2020
Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network
Loredana Amoroso, Victoria Castel, Gianni Bisogno, et al.
Child'S Nervous System : Chns : Official Journal of the International Society for Pediatric Neurosurgery
|
May 17, 2013
Somatostatin receptor subtype 2 (sst₂) is a potential prognostic marker and a therapeutic target in medulloblastoma
Marc Remke, Esther Hering, Nicolas U Gerber, et al.
Neuro-Oncology
|
April 5, 2024
Treatment response as surrogate to predict risk for disease progression in pediatric medulloblastoma with persistent magnetic resonance imaging lesions after first-line treatment
Denise Obrecht-Sturm, Lena Schömig, Martin Mynarek, et al.
Journal of Neurosurgery. Pediatrics
|
June 19, 2026
Incomplete tumor resection, central neuroradiological review, and second surgery in pediatric patients with intracranial ependymoma treated in the E-HIT2000 trial
Kara L Krajewski, Gertrud Kammler, Denise Obrecht-Sturm, et al.
Neuro-Oncology
|
April 28, 2021
Treatment of embryonal tumors with multilayered rosettes with carboplatin/etoposide induction and high-dose chemotherapy within the prospective P-HIT trial
B-Ole Juhnke, Marco Gessi, Nicolas U Gerber, et al.
Neuro-Oncology
|
June 3, 2026
Final report of the SIOP-CNS-GCT II protocol for germinoma-omitting radiotherapy boost is safe in localized disease in complete remission after chemotherapy
Gabriele Calaminus, Claire Alapetite, Rolf D Kortmann, et al.
Page
of 19